TITLE

New type 2 diabetes drug encourages weight loss

PUB. DATE
February 2013
SOURCE
Podiatry Now;Feb2013, Vol. 16 Issue 2, p13
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article reports that a new oral drug dapagliflozin is developed by Bristol-Myers Squibb, and AstraZeneca, a biopharmaceutical company which improves blood sugar control and promotes weight loss in type 2 diabetes patients.
ACCESSION #
86414014

 

Related Articles

  • Canagliflozin: A new option for managing diabetes. Livingston, Molly; Clements, Jennifer N. // JAAPA: Journal of the American Academy of Physician Assistants (;Sep2014, Vol. 27 Issue 9, p47 

    Canagliflozin is a sodium glucose cotransporter 2 inhibitor for patients with type 2 diabetes and can be given as monotherapy or in combination with other agents, including insulin. Taken orally once daily, canagliflozin can reduce weight and BP, but has been associated with genital mycotic...

  • Current Therapies and Emerging Drugs in the Pipeline for Type 2 Diabetes. Quang T. Nguyen; Thomas, Karmella T.; Lyons, Katie B.; Nguyen, Loida D.; Plodkowski, Raymond A. // American Health & Drug Benefits;Sep2011, Vol. 4 Issue 5, p303 

    Background: Diabetes is a global epidemic that affects 347 million people worldwide and 25.8 million adults in the United States. In 2007, the total estimated cost associated with diabetes in the United States in 2007 was $174 billion. In 2009, $16.9 billion was spent on drugs for diabetes. The...

  • When to use obesity drugs in diabetes? Haslam, David // Pulse;4/29/2009, Vol. 69 Issue 14, p34 

    The article provides an answer to a question of when can an obese patient diagnosed with type 2 diabetes uses weight-loss drugs.

  • Is Weight Loss a Cure for Type 2 Diabetes? Tayek, John A. // Diabetes Care;Feb2002, Vol. 25 Issue 2, p397 

    Editorial. Examines the effects of laparoscopic adjustable gastric band surgery on the development of type 2 diabetes, which resulted in an average weight loss of 27 kilograms on patients who participated in the surgery. Association of weight loss with an increase of serum high density...

  • St. Luke's seek participants in landmark diabetes study.  // New York Amsterdam News;2/13/2003, Vol. 94 Issue 7, p20 

    Reports that Saint Luke's-Roosevelt Hospital is looking for participants for Look AHEAD (Action for Health in Diabetes) study, the long-term study to look at effects of weight loss in people with Type 2 diabetes. Organization funding the study; Eligibility conditions for participants; Two...

  • Two views on couch potatoes: 1) Chances are most won't lose weight 2) How can you improve those...  // Modern Medicine;Aug94, Vol. 62 Issue 8, p28 

    Reports on an strategy in encouraging weight loss among noninsulin-dependent diabetics. Importance of the regulation of body fat and weight; Commitment of diabetics to lose weight.

  • High-Intensity Resistance Training Improves Glycemic Control in Older Patients With Type 2 Diabetes. Dunstan, David W.; De Courten, Maximilian; Shaw, Jonathan; Zimmet, Paul; Daly, Robin M.; Jolley, Damien; Owen, Neville // Diabetes Care;Oct2002, Vol. 25 Issue 10, p1729 

    OBJECTIVE -- To examine the effect of high-intensity progressive resistance training combined with moderate weight loss on glycemic control and body composition in older patients with type 2 diabetes. RESEARCH DESIGN AND METHODS -- Sedentary, overweight men and women with type 2 diabetes, aged...

  • Major drive to curb incidence of T2D.  // Practice Nurse;4/17/2015, Vol. 45 Issue 4, p10 

    The article reports on the national initiative launched by the National Health Service (NHS) England and Public Health England to reduce the incidence of type 2 diabetes by 2025. The importance of diabetes prevention through lifestyle change interventions is discussed. Seven innovative...

  • The Role of the Kidney and Sodium-Glucose Cotransporter-2 Inhibition in Diabetes Management. Valentine, Virginia // Clinical Diabetes;Fall2012, Vol. 30 Issue 4, p151 

    The article discusses the role of kidney and sodium-glucose cotransporter-2 (SGLT2) inhibition in diabetes management. The kidney plays a role in maintenance of blood glucose levels by the reabsorption of glucose. Therefore, the kidney has become a target of drug therapy for the treatment of...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics